When:
October 26, 2020 @ 7:28 am – October 26, 2021 @ 8:28 am
2020-10-26T07:28:00-04:00
2021-10-26T08:28:00-04:00

Diagnosing and Managing Primary Headache Disorders in the Primary Care Setting: Challenges and Opportunities

View Activity

FACULTY

Dawn Buse, PhD
Clinical Professor, Department of Neurology
Albert Einstein College of Medicine of Yeshiva University
Assistant Professor, Clinical Health Psychology Doctoral Program
Ferkauf Graduate School of Psychology of Yeshiva University
Board Member at Large, American Headache Society
Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at University of California
President-Elect, American Headache Society
Los Angeles, CA

PROGRAM OVERVIEW

This case-based enduring activity will cover the treatment and management of patients with headache disorders, including migraine and cluster headache.


TARGET AUDIENCE

This activity is intended for primary care providers, including family practice physicians, physician assistants, and nurse practitioners who are involved in the care of patients with headache disorders, including migraine and cluster headache.


LEARNING OBJECTIVES

  • Implement best practices for the timely and accurate diagnosis of primary headache disorders in primary care settings and for referral to specialists when necessary
  • Identify the mechanisms of action and clinical profiles of new and emerging therapeutic options for the acute and preventative treatment of patients with primary headache disorders
  • Design individualized evidence-based treatment plans for patients with primary headache disorders, with focus on cluster headache, in the primary care setting
  • Utilize patient-specific factors to select therapies for patients with primary headache disorders, including quality-of-life assessment and goal setting
  • Implement strategies to effectively communicate with patients and educate them in order to establish treatment plans and encourage adherence

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with headache disorders, including migraine and cluster headache.
CNE Credits: 1.5 ANCC Contact Hours.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dawn Buse, PhD has received consulting fees from
Amgen, Allergan, Biohaven, Dr. Reddy’s, Lilly, and Teva and research grant support from Amgen, Allergan,
Dr. Reddy’s, and Lilly.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
Andrew Charles, MD receives consulting fees from Alder, Amgen,
Biohaven, Eli Lilly, and eNeura. He has conducted research for Takeda Pharmaceuticals.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group, has nothing to disclose.
Chris Drury, Medical Director of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete pre-and-post surveys and evaluation.

Participants will receive their certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: October 26, 2020

EXPIRATION DATE: October 26, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group at info@medlearninggroup.com

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.